thioacetic acid N-phenyl-hydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: thioacetic acid N-phenyl-hydrazide
• 英文别名: N-Thioacetyl-N-phenyl-hydrazin；N-phenylethanethiohydrazide
• 化学式: C₈H₁₀N₂S
• 分子量: 166.247
• InChiKey: KDCRNHHXZZSLTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  2

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	1-Acetyl-1-phenylhydrazin	2116-41-8	C8H10N2O	150.18

反应信息

• 作为反应物：
  描述：

  thioacetic acid N-phenyl-hydrazide 、 二甲基丙二酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-N',3-N'-di(ethanethioyl)-2,2-dimethyl-1-N',3-N'-diphenylpropanedihydrazide
  参考文献：
  名称：

  Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol

  摘要：

  A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as anticancer agents by targeting oxidative stress and Hsp70 induction. Structure-activity relationship (SAR) studies lead to the discovery of STA-4783 (elesclomol), a novel small molecule that has been evaluated in a number of clinical trials as an anticancer agent in combination with Taxol. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.032
• 作为产物：
  描述：

  1-Acetyl-1-phenylhydrazin 在 P₂S₂ 作用下， 以 氘代苯 为溶剂， 生成 thioacetic acid N-phenyl-hydrazide
  参考文献：
  名称：

  Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol

  摘要：

  A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as anticancer agents by targeting oxidative stress and Hsp70 induction. Structure-activity relationship (SAR) studies lead to the discovery of STA-4783 (elesclomol), a novel small molecule that has been evaluated in a number of clinical trials as an anticancer agent in combination with Taxol. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.032

文献信息

• Treatment for cancers
  申请人：Synta Pharmaceuticals Corporation

  公开号：US20040225016A1

  公开（公告）日：2004-11-11

  One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I): 1 Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both>C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. R 1 -R 4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Preferably R 1 and R 2 are the same and R 3 and R 4 are the same. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Z is ═O or ═S.

  本发明的一种实施例是一种治疗多药耐药癌症患者的方法。该方法包括向患者施用式(I)所表示的化合物的有效量：其中1Y是共价键或取代或未取代的直链烃基，或Y与其结合的两个>C=Z基团一起形成取代或未取代的芳香族基团。R1-R4独立地为—H、脂肪基、取代脂肪基、芳基或取代芳基，或者R1和R3与它们结合的碳和氮原子以及/或R2和R4与它们结合的碳和氮原子形成一个非芳杂环环，可选地与芳环融合。最好的是R1和R2相同，R3和R4相同。R5-R6独立地为—H、脂肪基、取代脂肪基、芳基或取代芳基。Z为═O或═S。
• Mesoionische 1.3.4-thiadiazol-2-thione
  作者：Rudolf Grashey、Margit Baumann、Wolf-Dietmar Lubos

  DOI：10.1016/s0040-4039(00)75429-3

  日期：1968.1
• Mesoionische 1.3.4-thiadiazol-2-imine und 1.3.4-oxadiazol-2-imine
  作者：Rudolf Grashey、Rainer Hamprecht、Nikolaus Keramaris、Margit Baumann

  DOI：10.1016/s0040-4039(01)84978-9

  日期：1972.1
• Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol
  作者：Shoujun Chen、Lijun Sun、Keizo Koya、Noriaki Tatsuta、Zhiqiang Xia、Timothy Korbut、Zhenjian Du、Jim Wu、Guiqing Liang、Jun Jiang、Mitsunori Ono、Dan Zhou、Andrew Sonderfan

  DOI：10.1016/j.bmcl.2013.07.032

  日期：2013.9

  A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as anticancer agents by targeting oxidative stress and Hsp70 induction. Structure-activity relationship (SAR) studies lead to the discovery of STA-4783 (elesclomol), a novel small molecule that has been evaluated in a number of clinical trials as an anticancer agent in combination with Taxol. (C) 2013 Elsevier Ltd. All rights reserved.